Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 23;103(2):e209603.
doi: 10.1212/WNL.0000000000209603. Epub 2024 Jun 14.

Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis

Affiliations

Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis

Annebelle Michielsen et al. Neurology. .

Abstract

Background and objectives: Dysfunction of energy metabolism, cognition, and behavior are important nonmotor symptoms of amyotrophic lateral sclerosis (ALS), negatively affecting survival and quality of life, but poorly understood. Neuroimaging is ideally suited to studying nonmotor neurodegeneration in ALS, but few studies have focused on the hypothalamus, a key region for regulating energy homeostasis, cognition, and behavior. We evaluated, therefore, hypothalamic neurodegeneration in ALS and explored the relationship between hypothalamic volumes and dysregulation of energy metabolism, cognitive and behavioral changes, disease progression, and survival.

Methods: Patients with ALS and population-based controls were included for this cross-sectional and longitudinal MRI study. The hypothalamus was segmented into 5 subregions and their volumes were calculated. Linear (mixed) models, adjusted for age, sex, and total intracranial volume, were used to compare hypothalamic volumes between groups and to analyze associations with metabolism, cognition, behavior, and disease progression. Cox proportional hazard models were used to investigate the relationship of hypothalamic volumes with survival. Permutation-based corrections for multiple hypothesis testing were applied to all analyses to control the family-wise error rate.

Results: Data were available for 564 patients with ALS and 356 controls. The volume of the anterior superior subregion of the hypothalamus was smaller in patients with ALS than in controls (β = -0.70 [-1.15 to -0.25], p = 0.013). Weight loss, memory impairments, and behavioral disinhibition were associated with a smaller posterior hypothalamus (β = -4.79 [-8.39 to -2.49], p = 0.001, β = -10.14 [-15.88 to -4.39], p = 0.004, and β = -12.09 [-18.83 to -5.35], p = 0.003, respectively). Furthermore, the volume of this subregion decreased faster over time in patients than in controls (β = -0.25 [0.42 to -0.09], p = 0.013), and a smaller volume of this structure was correlated with shorter survival (hazard ratio = 0.36 [0.21-0.61], p = 0.029).

Discussion: We obtained evidence for hypothalamic involvement in ALS, specifically marked by atrophy of the anterior superior subregion. Moreover, we found that atrophy of the posterior hypothalamus was associated with weight loss, memory dysfunction, behavioral disinhibition, and survival, and that this subregion deteriorated faster in patients with ALS than in controls. These findings improve our understanding of nonmotor involvement in ALS and could contribute to the identification of new treatment targets for this devastating disease.

PubMed Disclaimer

Conflict of interest statement

M. van Es has consulted for Biogen, has received travel grants from Shire (formerly Baxalta), performs work as a medical monitor for an ongoing trial with Ferrer (NCT05178810, fees paid to institution), is a member of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD), and receives funding support from the Netherlands Organization for Health Research and Development (Vidi scheme), the Thierry Latran Foundation, the Motor Neurone Disease Association, FIGHT-MND, and the ALS Foundation Netherlands. J. Veldink has sponsored research agreements with Biogen and Astra Zeneca, outside the submitted work. L.H. van den Berg received grants from the Netherlands ALS Foundation, the Netherlands Organization for Health Research and Development (Vici scheme), The European Community's Health Seventh Framework Programme (grant number 259867; EuroMOTOR), the Netherlands Organization for Health Research and Development (STRENGTH project, funded through the EU Joint Programme-Neurodegenerative Disease Research), provides ad hoc consultancy services to Biogen, Ferrer, Amylyx, Takeda, and Argenx (payment received by institution) outside the submitted work, and is the Chair of the European Network for the Cure of ALS (ENCALS) and the Treatment Research Institute for the Cure of ALS (TRICALS). H.-J. Westeneng serves as medical monitor for Ferrer in the ADORE trial (NCT05178810). The other authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Difference in (Sub)hypothalamic Volumes Between Patients With ALS and Controls
Overview of hypothalamic atrophy in patients with ALS compared with controls. Blue regions represent significantly lower volumes in patients with ALS compared with controls after correction for multiple comparisons using permutations. Light gray regions represent no significant difference between groups. The image represents a left lateral view of the averaged left and right hypothalamic volumes. AIS = anterior inferior subregion; ALS = amyotrophic lateral sclerosis; ASS = anterior superior subregion; ITS = inferior tubular subregion; P = posterior subregion; STS = superior tubular subregion.
Figure 2
Figure 2. Hypothalamic Correlates of Weight Loss, Cognition, and Behavior
Overview of hypothalamic subregions correlated with weight loss at diagnosis (A), cognitive impairments (B, C), and behavioral changes (D, E). In (A), blue regions represent significantly lower volumes of hypothalamic subregions in ALS patients with weight loss compared with those without. Similarly, in (B), this is observed for patients with impaired memory scores, and in (C), for patients with impaired visuospatial scores. These significantly lower volumes (D) in patients with behavioral disinhibition, and (E) in patients experiencing loss of sympathy/empathy. All these differences are significant after correction for multiple comparisons using permutations. Light gray regions represent no significant difference between groups. The image represents a left lateral view of the averaged left and right hypothalamic volumes. AIS = anterior inferior subregion; ALS = amyotrophic lateral sclerosis; ASS = anterior superior subregion; ITS = inferior tubular subregion; P = posterior subregion; STS = superior tubular subregion.
Figure 3
Figure 3. Survival Curve for Patients With ALS
Time-to-event analysis according to posterior hypothalamic volume. The plot shows the observed Kaplan-Meier survival curve since first MRI scan, stratified for posterior hypothalamic volume below median (<109 mm3) and equal to or higher than median (≥109 mm3). Resulting p value (p = 0.001) was significant after correction for multiple testing using Bonferroni correction. ALS = amyotrophic lateral sclerosis.
Figure 4
Figure 4. Posterior Hypothalamic Deterioration in Patients With ALS and Controls
Interaction analysis to compare posterior hypothalamic change over time between patients with ALS and controls. The resulting p value (p = 0.029) was significant after correction for multiple comparisons using permutations. ALS = amyotrophic lateral sclerosis.

Similar articles

Cited by

References

    1. van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/S0140-6736(17)31287-4 - DOI - PubMed
    1. Mahoney CJ, Ahmed RM, Huynh W, et al. . Pathophysiology and treatment of non-motor dysfunction in amyotrophic lateral sclerosis. CNS Drugs. 2021;35(5):483-505. doi:10.1007/S40263-021-00820-1 - DOI - PubMed
    1. Vercruysse P, Vieau D, Blum D, Petersén Å, Dupuis L. Hypothalamic alterations in neurodegenerative diseases and their relation to abnormal energy metabolism. Front Mol Neurosci. 2018;11:2. doi:10.3389/FNMOL.2018.00002 - DOI - PMC - PubMed
    1. Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768 - DOI - PMC - PubMed
    1. Janse Van Mantgem MR, Van Eijk RPA, Van Der Burgh HK, et al. . Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91(8):867-875. doi:10.1136/JNNP-2020-322909 - DOI - PubMed